Scientists have uncovered why a specific strain of bacteria responsible for a meningitis B outbreak in Kent was particularly dangerous. Recent genetic analysis shows that this virulent strain acquired traits from harmless bacteria that normally live in the human throat. The outbreak, traced back to a venue in Canterbury in March 2026, resulted in 21 cases of invasive meningococcal disease (IMD) within seven days. Two teenagers died from the infection, and nine others required intensive care treatment. The study was conducted by specialists from the UK Health Security Agency (UKHSA) and researchers at Oxford University. They used bacterial genome sequencing to determine why this strain was so potent. The findings suggest that the meningitis B bacteria absorbed genetic material from other organisms through a process called horizontal gene transfer. This allows bacteria to gain new traits without reproducing. These genetic changes altered how the bacteria interact with human cells, making them more effective at causing severe illness and potentially affecting how the immune system recognizes them. According to the UKHSA, these invasive strains can appear suddenly and are difficult to predict, meaning similar outbreaks could happen again. Dr. Charlene Rodrigues, a consultant in pathogen genomics at the UKHSA, explained that the bacteria can change rapidly, sometimes acquiring new traits from nearby harmless bacteria that make them more likely to cause disease. She noted that the outbreak spread widely among young people due to the social environment, where close contact is common. Through genomic surveillance and sequencing of every case of invasive meningococcal disease in England, experts can detect unusual strains early and respond quickly. The research also suggests that the genetic changes that made this strain dangerous might explain why it did not continue to spread, although this was not predictable. Dr. Rodrigues emphasized the importance of continued surveillance, rapid response systems, vaccination, and public awareness of meningococcal disease symptoms. In response to the Kent outbreak, a one-time meningitis B vaccination program was launched to protect young people heading to university this autumn. Additionally, the Joint Committee on Vaccination and Immunisation (JCVI) recommended that teenagers should receive the vaccine on the NHS around age 15, with catch-up programs for those who might otherwise miss out. The findings will be presented at the UKHSA's annual conference in Manchester.